Export
Petrovax has been successfully operating in foreign pharmaceutical markets for more than 20 years.
The products are presented in 10 countries, including the EAEU, Middle East and European Union.
Export of original drugs increased by 61% in 2024.
The strategic goals of Petrovax are to increase the export potential and to expand the geography of sales.
The company plans to enter the markets of the Middle East, North African, Latin American and Asian countries.
- Armenia
- Azerbaijan
- Belarus
- Georgia
- Kazakhstan
- Kyrgyzstan
- Moldova
- Slovakia
- Turkmenistan
- Uzbekistan
Armenia
Cooperate from 2014
Products exported:
- Polyoxidonium®
- Longidaza®
- Velson®
- Uronext®
- Imoferaza®
Azerbaijan
Cooperate from 2011
Products exported:
- Polyoxidonium®
- Longidaza®
- ARTNEO®
Belarus
Cooperate from 2006
Products exported:
- Grippol® plus
- Polyoxidonium®
- Longidaza®
- VitaFerr®
- ARTNEO®
- Imoferaza®
Georgia
Cooperate from 2005
Products exported:
- Polyoxidonium®
- Longidaza®
Kazakhstan
Cooperate from 2006
Products exported:
- Grippol® plus
- Polyoxidonium®
- Longidaza®
- Uronext®
- Imoferaza®
Kyrgyzstan
Cooperate from 2005
Products exported:
- Grippol® plus
- Polyoxidonium®
- Longidaza®
- VitaFerr®
- Uronext®
- ARTNEO®
- Imoferaza®
Moldova
Cooperate from 2009
Products exported:
- Grippol® plus
- Polyoxidonium®
- Longidaza®
Slovakia
Cooperate from 2003
Products exported:
- Polyoxidonium®
Turkmenistan
Cooperate from 2018
Products exported:
- Grippol® plus
Uzbekistan
Cooperate from 2001
Products exported:
- Grippol® plus
- Polyoxidonium®
- Longidaza®
- Velson®
- Uronext®
For ten years, Petrovax has successfully confirmed compliance with the EU GMP certificate (Slovakia), which was first obtained in 2012
our competitive advantages
Original and in-demand portfolio of innovative products; patents for new molecules and pharmaceutical manufacturing technologies in Russia and abroad
High-tech biotechnological fill-cycle manufacturing in accordance with the EAEU and EU GMP standards: from the synthesis of the APIs to the release of FDF
R&D investment program and conducting international multicenter clinical trials of original products
Experience in implementing international projects in the production and R&D fields in cooperation with Big Pharma companies: Pfizer, Abbott, Boehringer Ingelheim, ISU Abxis
Petrovax is the winner in the categories "Exporter of the Year" and "Partnership of the Year" of the Russian Pharma Inspiration Awards—2021.
